Claims for Patent: 9,062,347

Summary for Patent: 9,062,347

Title:	Endothelin single nucleotide polymorphisms and methods of predicting .beta.-adrenergic receptor targeting agent efficacy
Abstract:	The present invention concerns the use of methods for evaluating .beta.-adrenergic receptor targeting agent treatment for a patient, particularly one with a heart condition. In general, the disclosed methods entail determining the presence or absence of one or more polymorphisms in an endothelin gene system member. Based on the results of this determination, a .beta.-adrenergic receptor targeting agent may be prescribed, administered or a treatment regimen altered, including the administration of a .beta.-blocker. Accordingly, methods of treatment are also described.
Inventor(s):	Taylor; Matthew R. G. (Denver, CO), Mestroni; Luisa (Boulder, CO)
Assignee:	The Regents of the University of Colorado, a body corporate (Denver, CO)
Application Number:	12/670,966
Patent Claims:	1. A method for treatment of a human patient with bucindolol comprising administering to the patient at least 50 mg of bucindolol formulated for oral administration after the patient is determined to be homozygous for guanine at position +356 in intron 4 of EDN1 (rs2071942) or homozygous for lysine at amino acid 198 of the EDN1 protein. 2. The method of claim 1, wherein the patient is determined to be homozygous by a method that comprises performing on the EDN1 gene from the patient pyrosequencing, chain terminating sequencing, restriction digestion, allele-specific polymerase reaction, single-stranded conformational polymorphism analysis, genetic bit analysis, temperature gradient gel electrophoresis, ligase chain reaction, or microarray hybridization. 3. The method of claim 1, wherein the patient is determined to be homozygous for guanine at position +356 in intron 4 of EDN1 (rs2071942) or homozygous for lysine at amino acid 198 of the EDN1 protein by obtaining a patient history. 4. The method of claim 1, further comprising obtaining a biological sample from the patient. 5. The method of claim 1, wherein the patient has symptoms of or has been diagnosed with a medical condition comprising heart failure or cardiomyopathy. 6. A method for treating a human patient with bucindolol comprising orally administering at least 50 mg bucindolol to the patient after the patient has been genotyped at nucleotide position +356 in intron 4 of EDN1 (rs2071942) of the patient and determined to be homozygous for guanine. 7. The method of claim 6, wherein the patient has been genotyped by a process comprising pyrosequencing, chain terminating sequencing, restriction digestion, allele-specific polymerase reaction, single-stranded conformational polymorphism analysis, genetic bit analysis, temperature gradient gel electrophoresis, ligase chain reaction, or microarray hybridization. 8. A method for treating a human patient with bucindolol comprising orally administering to the patient at least 50 mg of bucindolol after the patient has been genotyped at nucleotide position +61 in exon 5 of EDN1 (rs5370) and determined to be homozygous for a nucleotide encoding lysine. 9. The method of claim 8, wherein the patient has been genotyped by a process comprising pyrosequencing, chain terminating sequencing, restriction digestion, allele-specific polymerase reaction, single-stranded conformational polymorphism analysis, genetic bit analysis, temperature gradient gel electrophoresis, ligase chain reaction, or microarray hybridization.

Details for Patent 9,062,347

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2027-07-27
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2027-07-27
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2027-07-27